Cubist value jumps $250 million on Cubicin patent settlement with Teva
This article was originally published in Scrip
Executive Summary
Cubist Pharmaceuticals has confirmed that it has resolved patent infringement litigation with a unit of Teva Pharmaceutical Industries and has agreed to give Teva a licence to sell a generic version of its antibiotic Cubicin (daptomycin for injection) by 2018, or possibly by 2017.